Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 每经AI快讯，众生药业（SZ 002317，收盘价：23元）12月4日晚间发布公告称，近日，广东众生药业股 份有限公司（以下简称"公司"）控股子公司广东众生睿创生物科技有限公司（以下简称"众生睿创"）自 主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获得 国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液新增适应症进 行临床试验。 （记者 曾健辉） 2025年1至6月份，众生药业的营业收入构成为：医药制造占比96.13%，医药贸易占比3.29%，其他业务 占比0.58%。 截至发稿，众生药业市值为195亿元。 ...

代谢相关脂肪性肝炎(MASH)是由过量脂肪细胞引起的肝脏炎症，可导致进行性肝纤维化和肝硬化。 MASH的患者基数相当庞大，目前国内尚无专门获批用于治疗MASH的药物，存在巨大的未被满足的临 床治疗需求，因此开发有效的MASH治疗药物对改善患者的健康状况至关重要。 众生药业（002317）(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司(以 下简称"众生睿创")自主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝 炎"的药物临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225注射液新增适应症进行临床试验。 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验(REBUILDING-2研究)已 顺利启动并完成全部参与者入组工作;RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安慰 剂对照的 ...

RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验（REBUILDING-2研 究）已顺利启动并完成全部参与者入组工作；RAY1225注射液单药治疗2型糖尿病患者的安全性和有效 性、安慰剂对照的III期临床试验（SHINING-2）和RAY1225注射液与口服降糖药物联合治疗2型糖尿病 患者的安全性和有效性、司美格鲁肽注射液对照的III期临床试验（SHINING-3）两项降糖III期临床试验 目前参与者入组情况顺利。 格隆汇12月4日丨众生药业(002317.SZ)公布，公司控股子公司广东众生睿创生物科技有限公司（称"众 生睿创"）自主研发的一类创新多肽药物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物 临床试验获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液 新增适应症进行临床试验。 ...

RAY1225 能选择性结合并激活GLP-1受体和GIP受体，以葡萄糖依赖的方式促进胰岛素分泌和抑制胰高 血糖素从而控制血糖，同时抑制胃排空，抑制食欲，降低体重，降低外周胰岛素抵抗，改善肝脏脂肪变 性和气球样变等。RAY1225 的临床前研究结果表明，在MASH动物模型中RAY1225可改善的NAS评分 (评估肝脏炎症、坏死、纤维化等)、降低体重、改善脏体系数、糖脂代谢和肝脏脂肪水平，并呈现剂量 相关性，临床上有望用于MASH的治疗。 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和 GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前， RAY1225注射液用于治疗中国肥胖 /超重患者的安全性和有效性的III期临床试验(REBUILDING-2研究) 已顺利启动并完成全部参与者入组工作;RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安 慰剂对照的III期临床试验(SHINING-2)和RAY1225注射液与口服降糖药物联合治疗2型糖尿病患者的安 全性和有效性、司美格鲁肽注射液对照的III期临床试验(SHIN ...

人民财讯12月4日电，众生药业（002317）12月4日公告，控股子公司广东众生睿创生物科技有限公司自 主研发的一类创新多肽药物RAY1225注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获得 国家药监局批准，并收到《药物临床试验批准通知书》，同意RAY1225注射液新增适应症进行临床试 验。 ...

证券代码：002317 公告编号：2025-112 RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽 药物，具有GLP-1受体和GIP受体双重激动活性，得益于优异的药代动力学特性， 具备每两周注射一次的长效药物潜力。目前，RAY1225注射液用于治疗中国肥胖 /超重患者的安全性和有效性的III期临床试验（REBUILDING-2研究）已顺利启 第 1页 共 2页 广东众生药业股份有限公司 关于控股子公司收到一类创新药 RAY1225 注射液 新增适应症的药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）自主研发的一类创新多肽药 物 RAY1225 注射液新增适应症治疗"代谢相关脂肪性肝炎"的药物临床试验获 得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，同意 RAY1225 注射液新增适应症进行临床试验。具体情况如下： 一、《药物临床试验批准通知书》基本情况 根据《中华人民共和国药品管 ...

Core Viewpoint - The announcement indicates that the innovative peptide drug RAY1225 injection, developed by the subsidiary of the company, has received approval from the National Medical Products Administration for a new indication to treat "metabolism-related fatty liver disease" [1] Group 1 - The drug RAY1225 injection is classified as a first-class innovative peptide medication [1] - The approval includes a clinical trial for the new indication, which signifies a potential expansion of the drug's therapeutic applications [1] - The company has received the "Drug Clinical Trial Approval Notice" confirming the initiation of clinical trials for the new indication [1]

Core Viewpoint - The article discusses the recent developments in GLP-1/GIP dual receptor agonist RAY1225, highlighting its clinical research approval for treating metabolic-associated fatty liver disease (MASH) and its potential in weight management and diabetes treatment [5][6]. Group 1: Product Development - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has received implied approval for RAY1225, a long-acting GLP-1/GIP dual receptor agonist, for clinical research in MASH [5]. - RAY1225 is an innovative polypeptide drug developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., which has previously obtained clinical research approval for indications related to type 2 diabetes and overweight/obesity [5]. Group 2: Clinical Trials - The company announced results from the Phase II clinical trial (REBUILDING-1) for weight management, which included 172 participants who were either overweight or obese [6]. - Participants received RAY1225 (3 mg, 6 mg, 9 mg) or a placebo, with injections administered every two weeks over a 24-week treatment period [6]. - The dosing regimen included a gradual titration to target doses, with total administered doses of 30 mg for the 3 mg group, 50 mg for the 6 mg group, and 68 mg for the 9 mg group [6].

Core Insights - The demand for antiviral drugs has surged during the flu season, with significant increases in sales of Oseltamivir and Marbofloxacin, alongside the recent market entry of three new domestic antiviral drugs [1][3][5] Group 1: Market Demand and Sales Growth - The percentage of flu-like cases in China has risen, with a reported 40.9% positivity rate for flu tests during the 47th week of the year [2] - Sales data from various e-commerce platforms indicate a dramatic increase in antiviral drug demand, with Oseltamivir sales up 4.5 times and Marbofloxacin up 5 times from the previous week [3] - Overall sales of flu-related medications increased by 242% from November 24 to November 30 compared to the previous week, with specific products like Marbofloxacin and Oseltamivir seeing sales increases of 230% and 310%, respectively [3] Group 2: New Drug Approvals and Market Competition - Three new domestic antiviral drugs were approved in 2023, marking a significant increase in competition within the flu medication market [6][8] - The current market is primarily dominated by Oseltamivir and Marbofloxacin, but the entry of new competitors is reshaping the competitive landscape [8][9] - The sales of Oseltamivir reached 59 billion yuan in 2024, maintaining a leading market position despite the influx of generic alternatives [5][9] Group 3: Future Market Trends - The rapid growth of Marbofloxacin is notable, with a projected sales increase of over 758% in 2024, indicating a shift in market dynamics [9] - The competitive landscape is expected to intensify as more domestic companies enter the antiviral drug market, necessitating differentiation through innovation and market segmentation [10]